ProductsDistribution Products

ELIGARD

Therapeutic indication:

ELIGARD is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

 

ELIGARD 22.5 ELIGRAD 45mg
PRE-CONNECTED SYRINGE SYSTEM
סרטון הדרכה: 2 מזרקים סרטון הדרכה: מערכת של מזרקים מחוברים מראש
INSTRUCTIONS FOR RECONSTITUTION AND ADMINISTRATION FOR ELIGARD PRE-CONNECTED SYRINGE SYSTEM

 

 

  • Composition: Leuprorelin Acetate 22.5mg Leuprorelin Acetate 45mg
  • Method of administration: Subcutaneous
  • Manufacturer: Tolmar Pharmaceuticals Inc., USA